ACET Stock Overview
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Adicet Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.49 |
| 52 Week High | US$21.87 |
| 52 Week Low | US$7.42 |
| Beta | 1.99 |
| 1 Month Change | 11.27% |
| 3 Month Change | -59.14% |
| 1 Year Change | -43.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.87% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20
Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Oct 17Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?
Oct 04Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term
Aug 16Adicet Bio: A First Take
Jul 22Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
May 15We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Mar 18Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Feb 09Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management
Dec 28Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Dec 16Shareholder Returns
| ACET | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | -0.5% | 1.6% |
| 1Y | -43.6% | 2.9% | -10.8% |
Return vs Industry: ACET underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: ACET underperformed the US Market which returned -10.8% over the past year.
Price Volatility
| ACET volatility | |
|---|---|
| ACET Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ACET is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ACET's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 86 | Chen Schor | https://www.adicetbio.com |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin’s lymphoma.
Adicet Bio, Inc. Fundamentals Summary
| ACET fundamental statistics | |
|---|---|
| Market Cap | US$363.81m |
| Earnings (TTM) | -US$55.73m |
| Revenue (TTM) | US$30.46m |
11.9x
P/S Ratio-6.5x
P/E RatioIs ACET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACET income statement (TTM) | |
|---|---|
| Revenue | US$30.46m |
| Cost of Revenue | US$0 |
| Gross Profit | US$30.46m |
| Other Expenses | US$86.19m |
| Earnings | -US$55.73m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 100.00% |
| Net Profit Margin | -182.97% |
| Debt/Equity Ratio | 0% |
How did ACET perform over the long term?
See historical performance and comparison